Goodpasture Syndrome: Treatment in Refractory Anti-GBM Disease

This protocol addresses the management of Goodpasture syndrome in the setting of refractory anti-GBM disease — cases in which the condition has not been adequately controlled and further therapeutic options require consideration.

Clinical scenario: Refractory anti-GBM disease — Goodpasture syndrome that continues to pose management challenges and requires evaluation of additional treatment options beyond initial measures.

Treatment Approach

In this setting, a specific targeted agent may be considered as part of the management approach. The complete protocol — including agent, criteria for use, and clinical guidance — is available in full below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/kisup.2012.27

In refractory anti-GBM disease, rituximab may be tried.

View source ↗